Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Immunol. 2014 Apr 18;192(10):4592–4600. doi: 10.4049/jimmunol.1302517

Figure 1. Interactions between KIR-Better/Best donors and recipient HLA-C1 improve LFS and protect against relapse, especially in HLA-mismatched transplants.

Figure 1

Donors were assigned to KIR-Neutral and KIR-Better/Best groups based on KIR genotyping. Probabilities of LFS are provided by Kaplan Meier curves (A) and cumulative incidence probabilities are shown for relapse (B). Each outcome is shown comparing KIR-Neutral donors with KIR-Better/Best donors in HLA-C1/x recipients for all transplants (1), HLA-matched transplants (2) and the HLA-mismatched transplants (3). The estimated rates are presented for LFS and relapse at 5 years. P values were calculated from multivariate analyses comparing relative risks of outcomes for KIR-Neutral and KIR-Better/Best donor groups.